CN108778306A - 用于急剧升高一氧化氮水平的组合物和方法 - Google Patents

用于急剧升高一氧化氮水平的组合物和方法 Download PDF

Info

Publication number
CN108778306A
CN108778306A CN201680061891.9A CN201680061891A CN108778306A CN 108778306 A CN108778306 A CN 108778306A CN 201680061891 A CN201680061891 A CN 201680061891A CN 108778306 A CN108778306 A CN 108778306A
Authority
CN
China
Prior art keywords
extract
composition
nitric oxide
composition according
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680061891.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·L·特里普
C·J·达尔伯格
J·G·贝碧莎
M·卡迪格
W·高
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natural Sunlight Production Co
Original Assignee
Natural Sunlight Production Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natural Sunlight Production Co filed Critical Natural Sunlight Production Co
Publication of CN108778306A publication Critical patent/CN108778306A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
CN201680061891.9A 2015-08-28 2016-08-29 用于急剧升高一氧化氮水平的组合物和方法 Pending CN108778306A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562211673P 2015-08-28 2015-08-28
US62/211,673 2015-08-28
PCT/US2016/049306 WO2017040421A1 (en) 2015-08-28 2016-08-29 Compositions and methods for acutely raising nitic oxide levels

Publications (1)

Publication Number Publication Date
CN108778306A true CN108778306A (zh) 2018-11-09

Family

ID=58188359

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680061891.9A Pending CN108778306A (zh) 2015-08-28 2016-08-29 用于急剧升高一氧化氮水平的组合物和方法

Country Status (7)

Country Link
US (2) US11241406B2 (enExample)
EP (1) EP3341003A4 (enExample)
JP (1) JP2018530517A (enExample)
KR (1) KR20180043251A (enExample)
CN (1) CN108778306A (enExample)
CA (1) CA2996627A1 (enExample)
WO (1) WO2017040421A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10624921B2 (en) 2016-11-15 2020-04-21 Berkeley Nox Limited Dietary supplements
KR102705858B1 (ko) 2017-07-17 2024-09-10 아스트라제네카 아베 의약에서의 사용을 위한 mpo 억제제
WO2019055704A1 (en) * 2017-09-13 2019-03-21 Thermolife International, Llc ENRICHED ROOT POWDER PRODUCTS AND METHODS OF MAKING SAME
WO2019099003A2 (en) * 2017-11-15 2019-05-23 Berkeley Nox Limited Novel dietary supplements
JP7047440B2 (ja) * 2018-02-15 2022-04-05 三菱ケミカル株式会社 海綿体内圧上昇の増強剤並びにこれを含有する医薬組成物及び食品組成物
US10792320B2 (en) * 2018-03-28 2020-10-06 Michael Alan Beller Methods for treatment of bladder dysfunction
IT201800007747A1 (it) * 2018-08-01 2020-02-01 Pharmanutrition R&D Srl Formulazione nutraceutica per il controllo dell’ipertensione arteriosa da lieve a moderata
CN108936667A (zh) * 2018-08-29 2018-12-07 福建千叶百肽生物科技有限公司 一种多功能复合果蔬一氧化氮供体营养素及其制备方法
US12295981B2 (en) * 2018-10-01 2025-05-13 Astrogenesis Co., Ltd. Pharmaceutical composition for preventing or treating neurodegenerative diseases, containing Angelica gigas Nakai extract or mixed extract of Angelica gigas Nakai and broccoli
DK180173B1 (en) 2018-12-07 2020-07-14 Inxo Ivs Compositions for improving sexual function
US11571405B2 (en) 2018-12-07 2023-02-07 Inxo A/S Compositions for improving sexual function
JP2020182384A (ja) * 2019-04-26 2020-11-12 健商株式会社 経口組成物およびこれを含有する食品
WO2020231906A1 (en) * 2019-05-10 2020-11-19 Bgs Holdings Llc Sports and nutritional supplement formulations
US20220288149A1 (en) * 2019-08-14 2022-09-15 Innovus Pharmaceuticals, Inc. Sensitization cream comprising l-arginine and l-citrulline and therapeutic uses thereof
CA3052863C (en) 2019-08-23 2023-11-07 Spinal Relief Contres Of Canada Inc. Composition and method for forming a composition for increasing dermal nitric oxide
JP2022151714A (ja) * 2021-03-23 2022-10-07 花王株式会社 口腔内ナイセリア・ムコサ増加剤
KR102578902B1 (ko) * 2021-04-20 2023-09-13 단국대학교 천안캠퍼스 산학협력단 루꼴라 추출물을 함유하는 노인성 황반 변성 예방, 개선 및 치료용 조성물
EP4362955A1 (en) * 2021-06-28 2024-05-08 ASC REGENITY Limited Skin care nutraceutical composition
IT202100018509A1 (it) * 2021-07-14 2023-01-14 Biofficina Srls Bevanda funzionale con effetti benefici sulla sindrome metabolica
FR3127395B1 (fr) * 2021-09-27 2023-12-29 Nexira Composition orale antioxidante à base de plantes
US20250090729A1 (en) * 2022-01-20 2025-03-20 Cell and Molecular Tissue Engineering, LLC Methods and Products to Detect, Minimize and Treat TRAP-Related Tissue Reactions and Tissue Injury Associated With Medical Devices
US20250325611A1 (en) * 2024-04-23 2025-10-23 4Life Patents, Llc Immune modulation with enhanced endothelial nitric oxide synthetase activity

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059433A1 (en) * 1998-05-19 1999-11-25 Cooke Pharma Healthbar formulations
WO2004100896A2 (en) * 2003-05-13 2004-11-25 Giampapa Vincent C Anti-aging nutritional supplement
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
US8173837B1 (en) * 2009-12-03 2012-05-08 The United States of America, as represented by the Secretary of Agriculure Process for the production of L-citrulline from watermelon flesh and rind
US20120129818A1 (en) * 2009-04-23 2012-05-24 Desikan Rajagopal Compositions and Methods for Treatment of Cardiovascular Disease
US20130071371A1 (en) * 2009-06-15 2013-03-21 Neogenis Labs, Inc. Method of Producing Physiological and Therapeutic Levels of Nitric Oxide Through an Oral Delivery System
WO2014083438A2 (en) * 2012-11-09 2014-06-05 Abattis Bioceuticals Corp Nitric oxide increasing nutritional supplements and methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706756B1 (en) * 2001-11-16 2004-03-16 University Of South Florida Vasodilating compound and method of use
US6743449B2 (en) 2002-02-13 2004-06-01 Skinceuticals, Inc. Topical composition comprising olive leaf extract
US10835555B2 (en) 2007-02-26 2020-11-17 Heartbeet Ltd Compositions of nitrates and methods of use thereof
JP2010519336A (ja) 2007-02-26 2010-06-03 ルンドベルク，ヨン 亜硝酸塩及び硝酸塩及びこれらを含む組成物の新規使用
US10821132B2 (en) 2007-02-26 2020-11-03 Heartbeet Ltd Compositions of nitrates and methods of use thereof
HUE031982T2 (en) 2007-02-26 2017-08-28 Heartbeet Ltd Performance enhancing composition and use thereof
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US10426792B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid compositions
US8455531B2 (en) 2007-09-18 2013-06-04 Thermolife International, Llc Amino acid compositions
US8569368B2 (en) 2007-09-18 2013-10-29 Thermolife International, Llc Amino acid compounds
US8048921B2 (en) 2007-09-18 2011-11-01 Ronald Kramer Amino acid compounds
US10426750B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid supplement formulations
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US7777074B2 (en) 2007-09-18 2010-08-17 Thermolife International, Llc Amino acid compounds
US8569369B2 (en) 2007-09-18 2013-10-29 Thermolife International, Llc Amino acid compounds
US10435356B1 (en) 2007-09-18 2019-10-08 Thermolife International, Llc Amino acid compositions
US20100227925A1 (en) 2009-03-09 2010-09-09 Ruth Chatfield Sensitizing compound and method for increasing sexual sensitivity
US20150065943A1 (en) * 2013-08-27 2015-03-05 Matthew DeBow Method to Accelerate Healing

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059433A1 (en) * 1998-05-19 1999-11-25 Cooke Pharma Healthbar formulations
WO2004100896A2 (en) * 2003-05-13 2004-11-25 Giampapa Vincent C Anti-aging nutritional supplement
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
US20120129818A1 (en) * 2009-04-23 2012-05-24 Desikan Rajagopal Compositions and Methods for Treatment of Cardiovascular Disease
US20130071371A1 (en) * 2009-06-15 2013-03-21 Neogenis Labs, Inc. Method of Producing Physiological and Therapeutic Levels of Nitric Oxide Through an Oral Delivery System
US8173837B1 (en) * 2009-12-03 2012-05-08 The United States of America, as represented by the Secretary of Agriculure Process for the production of L-citrulline from watermelon flesh and rind
WO2014083438A2 (en) * 2012-11-09 2014-06-05 Abattis Bioceuticals Corp Nitric oxide increasing nutritional supplements and methods

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
LECTURER OF GENETICS，等: "Attenuation of Nano-TiO2 Induced Genotoxicity,Mutagenicity and Apoptosis by Chlorophyllin in Mice Cardiac Cells", 《INTERNATIONAL JOURNAL OF SCIENCE AND RESEARCH》 *
NICHOLS,等: "Skin photoprotection by natural polyphenols:Anti-inflammatory,anti-oxidant and DNA repair mechanisms", 《ARCHIVES OF DERMATOLOGICAL RESEARCH》 *
RAFIK BACHOUAL，等: "An aqueous pomegranate peel extract inhibits neutrophil myeloperoxidase in vitro and attenuates lung inflammation in mice", 《FOOD AND CHEMICAL TOXICOLOGY》 *
不详: "he Truth About Beet Juice", 《HTTP://WWW.WEBMD.COM》 *
不详: "ProArgi 9 Plus Site", 《HTTP://PROARGI9PLUSNG.BLOGSPOT.COM》 *
刘洪梅，等: "血清过氧化物酶及氧化氮与早发冠脉三支病变的关系", 《陕西医学杂志》 *
朱兆云，等主编: "《滇南本草.第3卷》", 31 December 2010, 云南科技出版社 *
杨立军: "葡萄多酚的研究概况", 《海峡药业》 *
郭红卫，主编: "《营养与食品安全》", 31 March 2005, 复旦大学出版社 *

Also Published As

Publication number Publication date
JP2018530517A (ja) 2018-10-18
WO2017040421A1 (en) 2017-03-09
EP3341003A1 (en) 2018-07-04
EP3341003A4 (en) 2019-04-03
KR20180043251A (ko) 2018-04-27
CA2996627A1 (en) 2017-03-09
US20180263944A1 (en) 2018-09-20
US11241406B2 (en) 2022-02-08
US20220296552A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US20220296552A1 (en) Compositions and methods for acutely raising nitic oxide levels
US11122832B2 (en) Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise
JP6903594B2 (ja) 食品、栄養補助食品、化粧品および医薬品に有用な複数の相乗的抗酸化活性を示すフィトコンプレックス
Mahomoodally et al. Nutritional, medicinal and functional properties of different parts of the date palm and its fruit (Phoenix dactylifera L.)–A systematic review
EP2288364B1 (en) Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
CN103313718B (zh) 生长激素分泌促进剂
US20150258038A1 (en) Stable and bioavailable compositions of isomers of carotenoids for skin and hair
CN102686113A (zh) 粗品咖啡因复合物、使用所述粗品咖啡因复合物的改进的食品及其使用方法
JP4371431B2 (ja) 抗アレルギー性組成物
JP5706142B2 (ja) フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、ｔｇ低下剤、糞中脂肪排泄促進剤
US20080175888A1 (en) Combination Therapy Comprising Actinidia and Steroids and Uses Thereof
JP2006016340A (ja) ザクロ抽出物を有効成分とする、血中尿酸値低下剤
HK1262460A1 (en) Compositions and methods for acutely raising nitic oxide levels
Brewer The Essential Guide to Vitamins, Minerals and Herbal Supplements
US12397030B2 (en) Polyphenol compositions and uses thereof
JP2007254322A (ja) 杉の葉抽出物及びこれを含む飲食物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1262460

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181109